Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Post-EHA 2026 MPN Highlights
24 June 2026 | Virtual Meeting
Post-EHA 2026 MPN Highlights
Featuring presentations & discussions on selected MPN abstracts from the 31st Congress of the European Hematology Association (EHA).
Chair: Claire Harrison | Moderators: John Mascarenhas & Jean-Jacques Kiladjian
The Post-EHA 2026 MPN Highlights has been supported by BMS (Platinum Sponsor) and Karyopharm Therapeutics (Silver Sponsor). Supporters have no influence over the production of content.
Session 1: Novel treatment approaches for ET & PV
Early versus delayed initiation of ropeginterferon alfa-2b in high-risk ET: two-year results from the Phase III SURPASS-ET study
Harinder Gill University of Hong Kong, Hong Kong
Mutant calreticulin-specific monoclonal antibody, INCA033989, is well tolerated and achieves rapid and sustained hematologic and molecular responses in patients with ET
John Mascarenhas Icahn School of Medicine at Mount Sinai, New York City, NY, United States
Benefit of rusfertide maintained in patients with low-risk or high-risk PV: efficacy and safety subgroup analysis from the VERIFY study
Valentin Garcia Gutiérrez Ramón y Cajal Hospital, Madrid, Spain
Divesiran, a novel galnac conjugated siRNA, reduces phlebotomies, improves iron stores and symptoms in PV: SANRECO study
Marina Kremyanskaya Icahn School of Medicine at Mount Sinai, New York City, NY, United States
Panel Discussion
Session 2: Latest in targeted therapies for myelofibrosis
Results of AJX-101, a Phase I clinical trial of AJ1-11095, in patients with myelofibrosis who have been failed by a type I JAK2 inhibitor
John Mascarenhas Icahn School of Medicine at Mount Sinai, New York City, NY, United States
Mutant calreticulin–specific monoclonal antibody, INCA033989, is well tolerated and achieves robust spleen, anemia, and molecular responses in patients with MF
Claire Harrison Guy’s and St. Thomas’ NHS Foundation Trust, London, United Kingdom
RALLY-MF: initial efficacy of a Phase II study of DISC-0974 to treat anemia in myelofibrosis
Naseema Gangat Mayo Clinic, Rochester, MN, United States
Efficacy and safety of luspatercept in patients with myelofibrosis on JAK inhibitors who require red blood cell transfusions: primary analysis of the INDEPENDENCE trial
Francesco Passamonti University of Insubria, Varese, Italy
Selinexor plus ruxolitinib in JAK inhibitor–naïve myelofibrosis: Phase III SENTRY trial
Claire Harrison Guy’s and St. Thomas’ NHS Foundation Trust, London, United Kingdom
Panel Discussion
Session 3: Novel approaches for MPNs, MPN-associated disease and mastocytosis
Development of a G6B directed antibody-drug conjugate for the treatment of MPNs
Adam Mead University of Oxford, Oxford, United Kingdom
MRD in myelofibrosis: clonal correlates from a prospective Phase II study
Nico Gagelmann University Medical Center Hamburg-Eppendorf, Hamburg, Germany
Antithrombotic and cytoreduction strategies in MPN-associated splanchnic vein thrombosis: a retrospective study from the French intergroup of myeloproliferative neoplasms
Alexandre Guy Bordeaux University Hospital, Bordeaux, France
Efficacy and safety of bezuclastinib in patients with advanced systemic mastocytosis: primary results from the APEX study
Daniel DeAngelo Dana-Farber Cancer Institute, Boston, MA, United States
Panel Discussion
